Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 8/20 | 0.48 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.48 |
| ▸ | CCR5 | P51681 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20139399 | 0.88 | SLC5A2 (0.42) | SLC5A2SLC5A1CCR5ALDH1A1 | |
| SCHEMBL20140005 | 0.81 | METAP1 (0.38) | SLC5A2SLC5A1CCR5 | |
| SCHEMBL20139385 | 0.81 | SLC5A1 (0.48) | SLC5A2SLC5A1PNMTASIC3MPO | |
| SCHEMBL30137005 | 0.80 | SLC5A2 (0.42) | SLC5A2SLC5A1 | |
| SCHEMBL10040915 | 0.80 | SLC5A2 (0.42) | SLC5A2SLC5A1 | |
| SCHEMBL20140006 | 0.78 | IL4I1 (0.36) | SLC5A2SLC5A1CCR5 | |
| SCHEMBL12782162 | 0.78 | CCR5 (0.47) | CCR5SLC6A4HTR2AKCNH2 | |
| SCHEMBL20139378 | 0.77 | CCR5 (0.36) | SLC5A2SLC5A1CCR5PNMTASIC3 | |
| SCHEMBL20139469 | 0.77 | SLC5A1 (0.51) | SLC5A2SLC5A1ALDH1A1 | |
| SCHEMBL20139435 | 0.77 | SLC5A2 (0.51) | SLC5A2SLC5A1MPOALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| WO-2018089449-A1 | BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885CCR5 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.